Project description:Gene expression analysis of 5-aza-dC treated pancreatic cancer associated fibroblasts To identify genes silenced by methylation in pancreatic CAFs, we performed gene expression profiling on 5-aza-dC treated pancreatic cancer associated fibroblast cultures using Affymetrix Exon arrays. We analyzed 5 untreated and 5-aza-dC-treated pancreatic cancer associated fibroblast cultures using the Affymetrix Human Exon 1.0 ST platform. Gene expression levels were compared using Partek (version 6.3beta).

2010-11-20 | E-GEOD-20911 | biostudies-arrayexpress

Gene expression-based, individualized outcome prediction for surgically treated pancreatic cancer patients

Project description:Gene expression-based, individualized outcome prediction for surgically treated pancreatic cancer patients

| PRJNA1035048 | ENA

Gene expression for surgically treated pancreatic cancer after one neoadjuvant vaccine dose

Project description:Gene expression for surgically treated pancreatic cancer after one neoadjuvant vaccine dose

| PRJNA516645 | ENA

Gene expression profiling of pancreatic cancer

Project description:Gene expression profiling of pancreatic cancer

| PRJNA488545 | ENA

Pancreatic cancer

Project description:Pancreatic cancer

| PRJNA1007691 | ENA

pancreatic cancer

Project description:pancreatic cancer

| PRJEB40742 | ENA

The gene expression differences between pancreatic cancer cell lines and its high liver metastatic lines

Project description:The gene expression differences between pancreatic cancer cell lines and its high liver metastatic lines

| PRJNA605289 | ENA

Pancreatic cancer cells treated with anlotinib

Project description:Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials. A comprehensive knowledge of the mechanism of angiogenesis inhibitors against pancreatic cancer is helpful for clinical purpose and for the selection of patients who might benefit from the inhibitors. In this work, multi-omics analyses (transcriptomics, proteomics and phosphoproteomics profiling) were carried to delineate the mechanism of anlotinib, a novel angiogenesis inhibitor, against pancreatic cancer cells.

2021-09-09 | PXD023344 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data